Abemaciclib approval and clinical use for HR+/HER2- early breast cancer
In this video clip, from Session 2, ‘Emerging adjuvant treatments for early breast cancer’, Dr Sara Tolaney outlines the FDA approval and usefulness of abemaciclib, a CDK4/6 inhibitor, for HR+/HER2- breast cancer.